Columvi (glofitamab) Letter of Medical Necessity
Columvi (glofitamab) is a bispecific antibody for relapsed DLBCL after two or more prior therapies. Prior authorization requires detailed documentation of prior treatment lines and consideration of CAR-T eligibility.
FDA-Approved Indications
- ● relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy
Why Columvi Prior Authorization Gets Denied
The most common denial reasons across major payers:
- 1. Prior lines of therapy not documented (requires ≥2 prior lines)
- 2. CAR-T therapy not considered or documented
- 3. DLBCL histology not confirmed
- 4. Obinutuzumab pretreatment protocol not addressed
- 5. ECOG performance status not documented
What to Include in a Columvi Letter of Medical Necessity
Document DLBCL diagnosis with histologic confirmation, all prior lines of systemic therapy with response and reason for discontinuation, CAR-T eligibility assessment, ECOG performance status, baseline labs, and tumor burden assessment.
Key clinical evidence to cite:
- ✓ NP30179 Phase I/II pivotal trial — 39% complete response rate in R/R DLBCL
Relevant guidelines:
- 📖 NCCN B-Cell Lymphoma Guidelines
- 📖 ASH/ASCO Guidelines for DLBCL Management
Columvi Prior Authorization Criteria
Standard criteria across major US payers for Columvi. Specific criteria vary by plan — RxCheckUp tailors each LMN to your patient's exact payer policy.
Typical step therapy requirements:
- → Prior lines of therapy not documented (requires ≥2 prior lines)
Required documentation:
- ✓ ICD-10 diagnosis code with specificity
- ✓ Prior therapy history with dates, doses, and discontinuation reasons
- ✓ Specialist evaluation (where applicable)
- ✓ Baseline disease activity or biomarker results
- ✓ Clinical rationale citing FDA labeling or guidelines
Approval details:
Initial approval: typically 6 months. Renewal: 12 months with documented clinical response.
Payers Covering Columvi
RxCheckUp tailors each LMN to the specific payer's medical policy and step therapy requirements:
Columvi Prior Authorization FAQ
Why was my Columvi prior authorization denied?
The most common denial reasons for Columvi are: Prior lines of therapy not documented (requires ≥2 prior lines); CAR-T therapy not considered or documented; DLBCL histology not confirmed; Obinutuzumab pretreatment protocol not addressed; ECOG performance status not documented.
What should a Columvi Letter of Medical Necessity include?
Document DLBCL diagnosis with histologic confirmation, all prior lines of systemic therapy with response and reason for discontinuation, CAR-T eligibility assessment, ECOG performance status, baseline labs, and tumor burden assessment.
Which payers cover Columvi?
Columvi is covered by major US payers including UnitedHealthcare, Aetna, Cigna, BCBS, Medicare Part B, though formulary tier and prior authorization criteria vary.